RT Journal Article
SR Electronic
T1 Ex-vivo mucolytic and anti-inflammatory activity of BromAc in tracheal aspirates from COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.23.21268347
DO 10.1101/2021.12.23.21268347
A1 Jordana Grazziela A. Coelho dos Reis
A1 Geovane Marques Ferreira
A1 Alice Aparecida Lourenço
A1 Ágata Lopes Ribeiro
A1 Camila Pacheco da Silveira Martins da Mata
A1 Patrícia de Melo Oliveira
A1 Daisymara Priscila de Almeida Marques
A1 Linziane Lopes Ferreira
A1 Felipe Alves Clarindo
A1 Murillo Ferreira da Silva
A1 Heitor Portella Póvoas Filho
A1 Nilson Roberto Ribeiro Oliveira Junior
A1 Maisah Meyhr D’Carmo Sodré
A1 Sandra Rocha Gadelha
A1 George Rego Albuquerque
A1 Bianca Mendes Maciel
A1 Ana Paula Melo Mariano
A1 Mylene de Melo Silva
A1 Renato Fontana
A1 Lauro Juliano Marin
A1 Renata Santiago Alberto Carlos
A1 Amanda Teixeira Sampaio Lopes
A1 Fabrício Barbosa Ferreira
A1 Uener Ribeiro dos Santos
A1 Íris Terezinha Santos de Santana
A1 Hllytchaikra Ferraz Fehlberg
A1 Rachel Passos Rezende
A1 João Carlos T Dias
A1 Eduardo Gross
A1 Gisele Assis Castro Goulart
A1 Marie Gabriele Santiago
A1 Ana Paula Motta Lavigne de Lemos
A1 Aline O da Conceição
A1 Carla Cristina Romano
A1 Luciana Debortoli de Carvalho
A1 Olindo Assis Martins Filho
A1 Claudio Almeida Quadros
A1 Sarah J Valle
A1 David L Morris
YR 2021
UL http://medrxiv.org/content/early/2021/12/23/2021.12.23.21268347.abstract
AB COVID-19 is a lethal disease caused by the pandemic SARS-CoV-2, which continues to be a public health threat. COVID-19 is principally a respiratory disease and is often associated with sputum retention, for which there are limited therapeutic options. In this regard, we evaluated the use of BromAc®, a combination of Bromelain and Acetylcysteine (NAC). Both drugs present mucolytic effect and have been studied to treat COVID-19. Therefore, we sought to examine the mucolytic, antiviral, and anti-inflammatory effect of BromAc® in tracheal aspirate samples from critically ill COVID-19 patients requiring mechanical ventilation.Method Tracheal aspirate samples from COVID-19 patients were collected following next of kin consent and mucolysis, rheometry and cytokine storm analysis was performed.Results BromAc® displayed a robust mucolytic effect in a dose dependent manner. BromAc® showed anti-inflammatory activity, reducing the action of cytokine storm, chemokines including MIP-1alpha, CXCL8, MIP-1b, MCP-1 and IP-10, and regulatory cytokines IL-5, IL-10, IL-13 IL-1RA and total reduction for IL-9 compared to NAC alone and control. BromAc® acted on IL-6, demonstrating a reduction in G-CSF and VEGF-D at concentrations of 125 and 250µg.Conclusion These results indicate robust mucolytic and anti-inflammatory effect of BromAc® in tracheal aspirates from critically ill COVID-19 patients, indicating its potential as a therapeutic strategy to COVID-19.Competing Interest StatementSJV and DLM are employed by Mucpharm Pty Ltd and provided scientific input on the protocol and design of the study.Funding StatementMucpharm Pty Ltd financially supported this project. In addition, we thank all Brazilian funding agencies CAPES, CNPq and FAPEMIG for providing funding to this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study followed the principles of Helsinki declaration as well as the resolution #466/2012 from the Brazilian Ministry of Health for research involving humans. This investigation was approved by the Santa Cruz State University (UESC) Institutional Brazilian Ethics Committee (Approval number: 45919121.6.0000.5526).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors